For these reasons, many PPARγ ligands have been proposed for the improvement of cognitive performance in different pathological conditions such as autism, schizophrenia, Parkinson’s disease, and Alzheimer’s disease [83,92]. This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.